Wall Street brokerages forecast that Atara Biotherapeutics Inc (NASDAQ:ATRA) will report earnings per share of ($1.18) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Atara Biotherapeutics’ earnings. The highest EPS estimate is ($1.17) and the lowest is ($1.18). Atara Biotherapeutics posted earnings per share of ($1.02) in the same quarter last year, which would indicate a negative year over year growth rate of 15.7%. The company is scheduled to report its next quarterly earnings report on Thursday, November 8th.
According to Zacks, analysts expect that Atara Biotherapeutics will report full-year earnings of ($4.58) per share for the current financial year, with EPS estimates ranging from ($4.59) to ($4.58). For the next financial year, analysts forecast that the business will post earnings of ($5.12) per share, with EPS estimates ranging from ($5.19) to ($5.05). Zacks’ EPS calculations are an average based on a survey of research firms that follow Atara Biotherapeutics.
Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported ($1.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.98) by ($0.17).
Several research analysts have recently commented on the company. BidaskClub downgraded Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, June 27th. Zacks Investment Research upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 10th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $45.00 price objective on shares of Atara Biotherapeutics in a report on Friday, August 3rd. Three analysts have rated the stock with a sell rating, two have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $47.80.
In related news, CEO Isaac E. Ciechanover sold 7,800 shares of the business’s stock in a transaction dated Friday, July 27th. The stock was sold at an average price of $38.00, for a total transaction of $296,400.00. Following the transaction, the chief executive officer now owns 812,613 shares in the company, valued at approximately $30,879,294. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Joe Newell sold 10,000 shares of the business’s stock in a transaction dated Monday, July 30th. The shares were sold at an average price of $35.78, for a total value of $357,800.00. Following the transaction, the insider now owns 41,858 shares in the company, valued at approximately $1,497,679.24. The disclosure for this sale can be found here. In the last quarter, insiders sold 93,575 shares of company stock worth $3,633,158. Company insiders own 10.60% of the company’s stock.
Large investors have recently made changes to their positions in the stock. SG Americas Securities LLC purchased a new position in Atara Biotherapeutics during the 1st quarter valued at about $107,000. Great West Life Assurance Co. Can increased its holdings in Atara Biotherapeutics by 100.1% during the 2nd quarter. Great West Life Assurance Co. Can now owns 3,309 shares of the biotechnology company’s stock valued at $121,000 after purchasing an additional 1,655 shares during the period. Bank of Montreal Can purchased a new position in Atara Biotherapeutics during the 2nd quarter valued at about $180,000. Principal Financial Group Inc. purchased a new position in Atara Biotherapeutics during the 1st quarter valued at about $214,000. Finally, Highland Private Wealth Management purchased a new position in Atara Biotherapeutics during the 2nd quarter valued at about $202,000.
ATRA opened at $36.42 on Friday. The stock has a market capitalization of $1.87 billion, a PE ratio of -9.11 and a beta of 2.54. Atara Biotherapeutics has a 12 month low of $12.65 and a 12 month high of $54.45.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Read More: How to Invest in Marijuana Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.